Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Health Technology Assessment

• Publication date

  2009-07-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.3310/hta13340PMID 19604457
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Economic Burden of Stroke in the United Kingdom

  2012cited by this paper
• Acute coronary syndrome: emerging tools for diagnosis and risk assessment.

  2010cited by this paper
• Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.

  2009cited by this paper
• Bortezomib for the treatment of multiple myeloma patients.

  2009cited by this paper
• patient-oriented and epidemiological research Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers

  2009cited by this paper
• Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.

  2009cited by this paper
• Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.

  2009cited by this paper
• The use of paclitaxel in the management of early stage breast cancer.

  2009cited by this paper
• Infliximab for the treatment of adults with psoriasis.

  2009cited by this paper
• Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.

  2009cited by this paper
• Erlotinib for the treatment of relapsed non-small cell lung cancer.

  2009cited by this paper
• A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease.

  2008cited by this paper
• Rosuvastatin: efficacy, safety and clinical effectiveness

  2008cited by this paper
• European cardiovascular disease statistics

  2008cited by this paper
• Statins, low-density lipoprotein cholesterol, and risk of cancer.

  2008cited by this paper
• Why doctors should worry about preemption.

  2008cited by this paper
• Coronary heart disease statistics.

  2008cited by this paper
• The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials

  2008cited by this paper
• Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.

  2008cited by this paper
• Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.

  2008cited by this paper
• Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

  2008cited by this paper
• Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.

  2008cited by this paper
• Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.

  2008cited by this paper
• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• Low LDL-C levels and cancer reassuring but still not definitive.

  2008cited by this paper
• Identifying and addressing safety signals in clinical trials.

  2008cited by this paper
• Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling.

  2008cited by this paper
• Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing.

  2007cited by this paper
• The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.

  2007cited by this paper
• Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.

  2007cited by this paper
• Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials

  2007cited by this paper
• Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery.

  2007cited by this paper
• Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.

  2007cited by this paper
• Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions.

  2007cited by this paper
• The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative Stress

  2007cited by this paper
• A COST-EFFECTIVENESS MODEL COMPARING ALTERNATIVE MANAGEMENT STRATEGIES FOR THE USE OF GLYCOPROTEIN IIB / IIIA ANTAGONISTS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME

  2007cited by this paper
• Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.

  2007cited by this paper
• Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE)

  2007cited by this paper
• Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.

  2007cited by this paper
• Statins and Cancer Risk: A Meta-analysis

  2007cited by this paper
• Rosuvastatin in older patients with systolic heart failure.

  2007cited by this paper
• Effect of simvastatin (80 mg) on coronary and abdominal aortic arterial calcium (from the coronary artery calcification treatment with zocor [CATZ] study).

  2007cited by this paper
• Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.

  2007cited by this paper
• Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.

  2007cited by this paper
• Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease

  2007cited by this paper
• Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease

  2007cited by this paper
• Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.

  2007cited by this paper
• Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia.

  2007cited by this paper
• The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: a randomized controlled study.

  2007cited by this paper
• Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).

  2007cited by this paper
• Therapy Insight: peripheral arterial disease and diabetes—from pathogenesis to treatment guidelines

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo‐controlled pilot study

  2007cited by this paper
• Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial Program

  2007cited by this paper
• A systematic review and economic evaluation of statins for the prevention of coronary events.

  2007cited by this paper
• Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial

  2007cited by this paper
• The role of statins in heart failure

  2007cited by this paper
• Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

  2006cited by this paper
• Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese.

  2006cited by this paper
• Statin safety: a systematic review.

  2006cited by this paper
• Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.

  2006cited by this paper
• Plasma Phospholipid Transfer Protein Activity Is Decreased in Type 2 Diabetes During Treatment With Atorvastatin

  2006cited by this paper
• Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

  2006cited by this paper
• Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.

  2006cited by this paper
• [The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].

  2006cited by this paper
• Statins and cancer risk: a meta-analysis.

  2006cited by this paper
• A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

  2006cited by this paper
• L'étude clinique du mois l'étude IDEAL comparant simvastatine 20-40 mg versus atorvastatine 80 mg en prévention après un infarctus du myocarde : entre deux idées de l'idéal

  2006cited by this paper
• SAFE (The Saline versus Albumin Fluid Evaluation) 試験

  2006cited by this paper
• Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation.

  2006cited by this paper
• Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.

  2006cited by this paper
• High doses of simvastatin in ACS decrease serum PDGF levels without influencing immune activation

  2006cited by this paper
• Statin-related adverse events: a meta-analysis.

  2006cited by this paper
• Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

  2006cited by this paper
• Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

  2006cited by this paper
• Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials

  2006cited by this paper
• The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery.

  2006cited by this paper
• The ASTEROID trial: coronary plaque regression with high-dose statin therapy.

  2006cited by this paper
• Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.

  2006cited by this paper
• Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation.

  2006cited by this paper
• Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial

  2006cited by this paper
• The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?

  2006cited by this paper
• Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.

  2006cited by this paper
• Early initiation of statin therapy in acute coronary syndromes: a review of the evidence.

  2005cited by this paper
• Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.

  2005cited by this paper
• Academic Editor: Chris Packard, Glasgow Royal Infirmary, United Kingdom

  2005cited by this paper
• Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.

  2005cited by this paper
• The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation.

  2005cited by this paper
• Safety of high-dose atorvastatin therapy.

  2005cited by this paper
• An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales.

  2005cited by this paper
• Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK.

  2005cited by this paper
• Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study.

  2005cited by this paper
• Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.

  2005cited by this paper
• Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia.

  2005cited by this paper
• Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis.

  2005cited by this paper
• Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis.

  2005cited by this paper
• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  2005cited by this paper
• The issue of statin safety: where do we stand?

  2005cited by this paper
• High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.

  2005cited by this paper
• Laparoscopic surgery for inguinal hernia repair: systematic review of effectiveness and economic evaluation.

  2005cited by this paper

• Cost-Utility Analysis of Rosuvastatin (20 mg) to Prevent Cardiovascular Diseases in Iran

  2024cites this paper
• beneits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation

  2020cites this paper
• Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review.

  2020cites this paper
• What are the cost-savings and health benefits of improving detection and management for six high cardiovascular risk conditions in England? An economic evaluation

  2020cites this paper
• Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?

  2020cites this paper
• Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease

  2018cites this paper
• Cost-Effectiveness and Value of Information Analysis of Brief Interventions to Promote Physical Activity in Primary Care.

  2018cites this paper
• Cost-Effective Hearing Conservation: Regulatory and Research Priorities

  2017cites this paper
• Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline

  2017influential citation
• Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation

  2017cites this paper
• Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States

  2017cites this paper
• Structural Changes in the Skeletal Muscle Fiber of Adult Male AlbinoRat Following Atorvastatin Treatment; the Possible Mechanisms ofAtorvastatin Induced Myotoxicity

  2017cites this paper
• The impact of Type 2 diabetes prevention programmes based on risk‐identification and lifestyle intervention intensity strategies: a cost‐effectiveness analysis

  2017cites this paper
• Screening for glucose intolerance and development of a lifestyle education programme for prevention of Type 2 diabetes in a population with intellectual disabilities

  2017cites this paper
• Type 2 diabetes: prevention in people at high risk

  2017cites this paper
• Impact Factors and Attitudes Toward Organ Donation Among Transplantation Patients and Their Caregivers in China.

  2017cites this paper
• An evidence based approach to the use of telehealth in long-term health conditions: Development of an intervention and evaluation through pragmatic randomised controlled trials in patients with depression or raised cardiovascular risk

  2017cites this paper
• Ezetimibe-Statin Combination Therapy.

  2016cites this paper
• Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

  2016cites this paper
• Cost-effectiveness modelling of telehealth for patients with raised cardiovascular disease risk: evidence from a cohort simulation conducted alongside the Healthlines randomised controlled trial

  2016cites this paper
• Retracted: Impact of Type 2 diabetes prevention programmes based on risk identification and lifestyle intervention intensity strategies: a cost‐effectiveness analysis

  2016cites this paper
• The Impact of Excluding Trials from Network Meta-Analyses – An Empirical Study

  2016cites this paper
• The Combination of Green Tea Extract and Eriodictyol Inhibited High-Fat/High-Sucrose Diet-Induced Cholesterol Upregulation Is Accompanied by Suppression of Cholesterol Synthesis Enzymes.

  2016cites this paper
• Does the addition of ezetimibe to statins reduce cardiovascular risk?

  2016cites this paper
• Sensitivity to Excluding Treatments in Network Meta-analysis

  2016cites this paper
• NCDMod: A Microsimulation Model Projecting Chronic Disease and Risk Factors for Australian Adults

  2015influential citation
• SPHR Diabetes Prevention Model: Detailed Description of Model Background, Methods, Assumptions and Parameters

  2015cites this paper
• Statins for acute coronary syndrome.

  2014cites this paper
• Target-attainment rates of low-density lipoprotein cholesterol using lipid-lowering drugs one year after acute myocardial infarction in sweden.

  2014cites this paper
• The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer

  2014cites this paper
• Rosuvastatin calcium in acute coronary syndromes

  2013cites this paper
• Evaluation of inconsistency in networks of interventions.

  2013cites this paper
• Economic Evaluation of Cardio inCode®, a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment

  2013cites this paper
• Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.

  2013cites this paper
• Stochastic control methods to individualise drug therapy by incorporating pharmacokinetic, pharmacodynamic and adverse event data

  2013cites this paper
• The effects of excluding treatments from network meta-analyses: survey

  2013cites this paper
• Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients.

  2013cites this paper
• Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures

  2012cites this paper
• Individual participant data meta-analysis of prognostic factor studies: state of the art?

  2012cites this paper
• Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain

  2012cites this paper
• Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?

  2012cites this paper
• Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients.

  2012cites this paper
• What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

  2012cites this paper
• Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL

  2011cites this paper
• Intensive statin therapy for Indians: Part-I. Benefits.

  2011cites this paper
• Maximizing the impact of systematic reviews in health care decision making: a systematic scoping review of knowledge-translation resources.

  2011cites this paper
• Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.

  2011cites this paper
• Statins for acute coronary syndrome.

  2011cites this paper
• Efficacia clinica e costo-efficacia di atorvastatina a elevati dosaggi nella prevenzione degli eventi cardiocerebrovascolari

  2011cites this paper
• Evaluaciones económicas de tecnologías sanitarias: una perspectiva global para su aplicación en América Latina

  2011cites this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cites this paper
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

  2010cites this paper
• Evaluation of the law of presumed consent after brain death by Spanish journalism students.

  2010cites this paper
• Health related quality of life by age, gender and history of cardiovascular disease: results from the Health Survey for England

  2009cites this paper
• Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective

  2009influential citation
• Sekundärprophylaxe des Schlaganfalls nach PRoFESS und SPARCL

  2009cites this paper
• Survival Online: a web-based service for the analysis of correlations between gene expression and clinical and follow-up data

  2009cites this paper
• Cost Effectiveness of Ezetimibe in Patients with Cardiovascular Disease and Statin Intolerance or Contraindications

  2008cites this paper
• Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.

  2008cites this paper